Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K0VO
|
|||
| Former ID |
DNC001490
|
|||
| Drug Name |
Urapidil
|
|||
| Synonyms |
urapidil; 34661-75-1; Ebrantil; Eupressyl; Mediatensyl; Uraprene; Urapidilum [INN-Latin]; UNII-A78GF17HJS; NSC 310405; B-66256; C20H29N5O3; EINECS 252-130-4; BRN 0725782; A78GF17HJS; MLS003115907; 6-(3-(4-(o-Methoxyphenyl)-1-piperazinyl)propylamino)-1,3-dimethyluracil; 6-[[3-[4-(2-Methoxyphenyl)-1-piperazinyl]propyl]amino]-1,3-dimethyluracil; NCGC00016066-07; Ebrantil (TN); 6-((3-(4-(o-Methoxyphenyl)-1-piperazinyl)propyl)amino)-1,3-dimethyluracil; W-106718; Urapidilum; urapidil(jan); TgAAV-TNFR:Fc
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Inflammation [ICD-11: 1A00-CA43.1] | Phase 1/2 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H29N5O3
|
|||
| Canonical SMILES |
CN1C(=CC(=O)N(C1=O)C)NCCCN2CCN(CC2)C3=CC=CC=C3OC
|
|||
| InChI |
1S/C20H29N5O3/c1-22-18(15-19(26)23(2)20(22)27)21-9-6-10-24-11-13-25(14-12-24)16-7-4-5-8-17(16)28-3/h4-5,7-8,15,21H,6,9-14H2,1-3H3
|
|||
| InChIKey |
ICMGLRUYEQNHPF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 34661-75-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
455193, 5416504, 7848396, 8153468, 11111935, 11111936, 11114211, 11341954, 11362137, 11364254, 11366816, 11369378, 11372633, 11374064, 11377540, 11466933, 11468053, 11484919, 11486685, 11487539, 11488988, 11491372, 11492048, 11495174, 12014605, 14902854, 26612398, 26680529, 26747180, 26747181, 26752246, 29224676, 47216940, 47216941, 47216942, 47515487, 47810932, 48035312, 48110622, 48414617, 49699376, 50059584, 50104955, 50122971, 50122972, 57322878, 77058650, 81041248, 85213182, 85787105
|
|||
| ChEBI ID |
CHEBI:32278
|
|||
| SuperDrug ATC ID |
C02CA06
|
|||
| SuperDrug CAS ID |
cas=034661751
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 1A receptor (HTR1A) | Target Info | Agonist | [3] |
| Adrenergic receptor Alpha-1 (ADRA1) | Target Info | Antagonist | [3] | |
| KEGG Pathway | cAMP signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT1 type receptor mediated signaling pathway | ||||
| Reactome | Serotonin receptors | |||
| G alpha (i) signalling events | ||||
| WikiPathways | Serotonin HTR1 Group and FOS Pathway | |||
| SIDS Susceptibility Pathways | ||||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | Secretion of a TNFR:Fc fusion protein following pulmonary administration of pseudotyped adeno-associated virus vectors. J Virol. 2004 Nov;78(22):12355-65. | |||
| REF 3 | Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.